Researchers around the world have been studying a group of recently-identified antibodies capable of neutralizing most strains of HIV, with the hopes of developing a vaccine that produces antibodies with these same properties.
(Credit: Alejandro Balazs/California Institute of Technology)
Now, biologists out of the California Institute of Technology--led by Nobel Laureate David Baltimore--are one step closer to a vaccine with their new method of delivering these antibodies to lab mice, thereby protecting them from HIV.
Their approach, calledVectored ImmunoProphylaxis(VIP) and outlined in today's online issue of Nature, turns the traditional vaccination method on its head.
For the most part, researchers have focused on designing substances that activate the immune system to do one of two things: block infection via antibodies, or attack infected cells via T cells. But the VIP approach provides protective antibodies from the start.